ROGAINE Rx-TO-OTC SWITCH STUMBLES ON ISSUE OF BALDNESS MISDIAGNOSIS: ADVISORY COMMITTEE SPLITS HAIRS ABOUT "MEANINGFUL" EFFICACY; ACTUAL-USE STUDY URGED
Upjohn's attempt to have Rogaine switched from Rx to OTC status stumbled on the issue of potential consumer misdiagnosis of the masons behind balding, resulting in a 10-4 vote against approval of the switch of topical minoxidil 2% at a July 27 meeting of the Nonprescription Drugs Advisory Committee.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth